<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1816-8949</journal-id>
<journal-title><![CDATA[Anales de la Facultad de Ciencias Médicas (Asunción)]]></journal-title>
<abbrev-journal-title><![CDATA[An. Fac. Cienc. Méd. (Asunción)]]></abbrev-journal-title>
<issn>1816-8949</issn>
<publisher>
<publisher-name><![CDATA[EFACIM. Editorial de la Facultad de Ciencias Médicas - Universidad Nacional de Asunción]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1816-89492025000200096</article-id>
<article-id pub-id-type="doi">10.18004/anales/2025.058.02.96</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Terapia Intravítrea en Toxoplasmosis Ocular: Un Enfoque alternativo para la Preservación de la Visión]]></article-title>
<article-title xml:lang="en"><![CDATA[Intravitreal Therapy in Ocular Toxoplasmosis: An alternative approach for Vision Preservation]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mañotti Galeano]]></surname>
<given-names><![CDATA[Jazmín Marlene]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mujica Valinotti]]></surname>
<given-names><![CDATA[Luis Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vallory-Gosset]]></surname>
<given-names><![CDATA[Tania Karina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González Cabral]]></surname>
<given-names><![CDATA[Mauricio Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortiz Gómez]]></surname>
<given-names><![CDATA[Sebastián Rodolfo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fleitas Armoa]]></surname>
<given-names><![CDATA[Fernando Nicolas]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez Franco]]></surname>
<given-names><![CDATA[Marcelo María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Asunción Facultad de Ciencias Médicas, Cátedra y Servicio de Oftalmología Fundación Banco de Ojos Fernando Oca del Valle]]></institution>
<addr-line><![CDATA[San Lorenzo ]]></addr-line>
<country>Paraguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Banco de Ojos &#8220;Fernando Oca del Valle&#8221;.  ]]></institution>
<addr-line><![CDATA[San Lorenzo ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2025</year>
</pub-date>
<volume>58</volume>
<numero>2</numero>
<fpage>96</fpage>
<lpage>100</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S1816-89492025000200096&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S1816-89492025000200096&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S1816-89492025000200096&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La toxoplasmosis ocular con afectación foveal es una entidad poco frecuente que puede comprometer gravemente la agudeza visual. Se presenta un caso de primoinfección diagnosticada en un paciente joven y tratada con terapia intravítrea como enfoque alternativo para la preservación de la visión.  Objetivo:  Describir la evolución clínica y visual de un paciente con toxoplasmosis ocular activa y afectación foveal tratado con clindamicina y dexametasona intravítreas.  Material y Métodos:  Estudio observacional retrospectivo tipo reporte de caso clínico, con seguimiento a corto plazo. Hombre de 18 años que acudió a consulta por disminución de la agudeza visual en el ojo derecho de tres días de evolución, precedido por la aparición de manchas negras. Fue atendido en el Servicio de Retina del Departamento de Oftalmología de la Fundación Banco de Ojos &#8220;Fernando Oca del Valle&#8221;, sede externa de la Universidad Nacional de Asunción, en Asunción, Paraguay. La exploración inicial mostró reacción en cámara anterior, lesión activa de coriorretinitis foveal en el fondo de ojo, y agudeza visual cuenta dedos a un metro. Se confirmó primoinfección mediante serología específica. Se administraron tres ciclos de clindamicina (1 mg/0.1 mL) y dexametasona (400 &#956;g/0.1 mL) intravítreas en intervalos de quince días durante un periodo de seguimiento de tres meses.  Resultados:  Tras tres meses de seguimiento con tratamiento intravítreo, el paciente presentó una mejoría visual parcial en el ojo derecho, alcanzando una agudeza visual de 20/150. Persistía un escotoma central relativo. El examen de fondo de ojo evidenció una cicatriz foveal bien delimitada, sin signos de actividad inflamatoria residual.  Discusión:  Este caso resalta el papel de la terapia intravítrea como opción efectiva para manejar infecciones oculares activas con compromiso visual severo, minimizando secuelas permanentes.  Conclusión:  La intervención temprana con terapia intravítrea es una alternativa eficaz en casos seleccionados de toxoplasmosis ocular activa con afectación foveal.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Ocular toxoplasmosis with foveal involvement is a rare entity that can seriously compromise visual acuity. We present a case of primary infection diagnosed in a young patient and treated with intravitreal therapy as an alternative approach for vision preservation.  Objective:  To describe the clinical and visual evolution of a patient with active ocular toxoplasmosis and foveal involvement treated with intravitreal clindamycin and dexamethasone.  Material and Methods:  Retrospective observational study in the form of a clinical case report, with short-term follow-up. An 18-year-old male presented with decreased visual acuity in the right eye for the past three days, preceded by the appearance of black floaters. He was evaluated at the Retina Service of the Department of Ophthalmology of the Fundación Banco de Ojos &#8220;Fernando Oca del Valle,&#8221; an external site of the National University of Asunción, in Asunción, Paraguay. Initial examination revealed anterior chamber reaction, an active foveal chorioretinitis lesion on fundus examination, and visual acuity of counting fingers at one meter. Primary infection was confirmed through specific serology. Three cycles of intravitreal clindamycin (1 mg/0.1 mL) and dexamethasone (400 &#956;g/0.1 mL) were administered at fifteen-day intervals during a three-month follow-up period.  Results:  After three months of follow-up with intravitreal treatment, the patient showed partial visual improvement in the right eye, reaching a visual acuity of 20/150. A relative central scotoma persisted. Fundus examination revealed a well-defined foveal scar without signs of residual inflammatory activity.  Discussion:  This case highlights the role of intravitreal therapy as an effective option to manage active ocular infections with severe visual compromise, minimizing permanent sequelae.  Conclusion:  Early intervention with intravitreal therapy is an effective alternative in selected cases of active ocular toxoplasmosis with foveal involvement.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Toxoplasmosis ocular]]></kwd>
<kwd lng="es"><![CDATA[terapia intravítrea]]></kwd>
<kwd lng="es"><![CDATA[clindamicina]]></kwd>
<kwd lng="es"><![CDATA[dexametasona.]]></kwd>
<kwd lng="en"><![CDATA[Ocular toxoplasmosis]]></kwd>
<kwd lng="en"><![CDATA[intravitreal therapy]]></kwd>
<kwd lng="en"><![CDATA[clindamycin]]></kwd>
<kwd lng="en"><![CDATA[dexamethasone.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Facio Lince]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[López De Mesa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Torre]]></surname>
<given-names><![CDATA[A de la]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toxoplasmosis ocular en Colombia: 10 años de aportes investigativos]]></article-title>
<source><![CDATA[Rev Soc Colomb Oftalmol.]]></source>
<year>2018</year>
<volume>51</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>16-28.</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardozo]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Mesquita]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Godoy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toxoplasmosis ocular: frecuencia y características clínicas en un consultorio de oftalmología pediátrica]]></article-title>
<source><![CDATA[Pediatr (Asunción).]]></source>
<year>2018</year>
<volume>45</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>223-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zamora]]></surname>
<given-names><![CDATA[YF]]></given-names>
</name>
<name>
<surname><![CDATA[Arantes]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Reis]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Saraceno]]></surname>
<given-names><![CDATA[JJF]]></given-names>
</name>
<name>
<surname><![CDATA[Belfort]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Local treatment of toxoplasmic retinochoroiditis with intravitreal clindamycin and dexamethasone.]]></article-title>
<source><![CDATA[Arq Bras Oftalmol.]]></source>
<year>2015</year>
<volume>78</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>216-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soheilian]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ramezani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Azimzadeh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sadoughi]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Dehghan]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Shahghadami]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis.]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2011</year>
<volume>118</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>134-41</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sobrin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kump]]></surname>
<given-names><![CDATA[LI]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[CS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravitreal clindamycin for toxoplasmic retinochoroiditis.]]></article-title>
<source><![CDATA[Retina]]></source>
<year>2007</year>
<volume>27</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>952-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hosseini]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Abrishami]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mehdi Zadeh]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravitreal clindamycin in the treatment of unresponsive zone one toxoplasmic chorioretinitis: a case report]]></article-title>
<source><![CDATA[Iran Red Crescent Med J.]]></source>
<year>2014</year>
<volume>16</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jorge]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[IN]]></given-names>
</name>
<name>
<surname><![CDATA[Silva-Cunha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandes Cunha]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[IU]]></given-names>
</name>
<name>
<surname><![CDATA[Fialho]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis]]></article-title>
<source><![CDATA[Am J Ophthalmol Case Rep.]]></source>
<year>2021</year>
<volume>22</volume>
<page-range>101093</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tabuenca del Barrio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Heras Mulero]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mozo Cuadrado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fanlo Mateo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Compains Silva]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravitreal clindamycin as a therapeutic alternative in severe ocular toxoplasmosis.]]></article-title>
<source><![CDATA[Arch Soc Esp Oftalmol (Engl Ed)]]></source>
<year>2019</year>
<volume>94</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>602-4.</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
